Integrative bulk and single-cell transcriptomics define a metabolic risk score and suggest an LDHA–lactate–HCAR1 axis linked to an immunosuppressive macrophage state in glioblastoma
Year: 2026
Type: article
Abstract: Glioblastoma (GBM) resists immunotherapy, and its lactate-rich microenvironment may be part of the reason. Whether metabolic prognosis connects to lactate-driven immune suppression remains unclear. We built a metabolic risk score (MRS) from 410 dysregulated metabolic genes in TCGA-GBM using LASSO-Cox regression, with all survival analyses performed at the patient level. We then mapped the metabolic–immune landscape in 24,131 single cells spanning 34 annotated cell types. Finally, we tested an LDHA–lactate–HCAR1 axis in U87MG and THP-1 cells and docked lactate into HCAR1 (PDB 8Z8A). The patient-level model (286 unique patients, 231 events) retained 53 features, and the standardized MRS was associated with survival (hazard ratio 2.81 per SD, 95% CI 2.38–3.32), remaining significant after adjustment for age and gender; internal validation gave a bootstrap-corrected concordance index of 0.629, so the score is best read as a proof of principle. A glycolysis score alone did not stratify survival (log-rank p = 0.53). In the single-cell data, malignant cells carried the highest glycolysis scores and CellChat inferred prominent macrophage-directed PTN/APP/MK signaling, although a quantitative test found no significant correlation between malignant glycolysis and macrophage-directed signaling. LDHA knockdown lowered macrophage IL-10 from 71.1 to 41.0 pg/mL, and lactate add-back partly restored it. Re-docking lactate into HCAR1 validated the docking protocol (RMSD 0.70 Å; score − 4.63 kcal/mol), and HCAR1 knockdown was followed by altered extracellular lactate and, in a preliminary experiment, attenuated TNF-α suppression. These data suggest a dual immunosuppressive role for LDHA in GBM. The LDHA–lactate–HCAR1 axis points to a candidate therapeutic vulnerability, but its clinical value still needs validation.
Source: Discover Oncology
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,690
OpenAlex ID: W7237360509
FWCI:
Cites:
Cited by:
Related to:
